New clinical trial results show that undergoing high-dose immunosuppressive therapy and then having the patient’s blood-forming stem cells transplanted brings on the reduction of relapsing-remitting multiple sclerosis (MS). MS is an autoimmune disease in which the central nervous system gets attacked by the immune system. The treatment is called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HTC). Five years after participants had received treatment; sixty-nine percent of them didn’t have any new brain lesions and did not experience symptoms of MS.
Studies have revealed that other methods of treatment have not been as successful as HDIT/HTC. The trial, named HALT-MS was funded by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID-sponsored Immune Tolerance Network (ITN) conducted the study, of which the five-year results appeared in the American Academy of Neurology’s journal Neurology. NIAID director Anthony S. Fauci said that the extended findings suggest that a one-time treatment with HDIT/HTC may be better than any long-term medication given to people with any type of MS. The purpose of the experiment was to remove the disease-causing cells and keep the immune system in its normal state.
Dr. Shiva Gopal Vasishita is a practicing neurologist at Voorhees, New Jersey who works with the Kennedy National Hospital. He is among the 34 doctors in the hospital who specialize in neurology. Dr. Shiva Vasishita has an experience of over 38 years of experience in his area of expertise. He received his medical degree from Government Medical School Nagpur in 1979.
Dr. Gopal Vasishita is a member of the practice group known as Eastern Neurodiagnostic Associates and is also an expert in psychiatry. Dr. Gopal Vasishita accepts various insurance plans which include: Horizon Blue Cross Blue Shield, Aetna, and Medicare. He is a certified neurologist, licensed to practice in New Jersey (his license number is 25MA55133). His current place of practice is 2301 Evesham Road, Pavilion 800 Suite 2009, Voorhees, NJ.